Tobias W. Holderried

Aachen, NW, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Aachen, NW, DE 

Overview

Tobias Holderried practices practicing medicine in Aachen, Germany.

His clinical expertise encompasses Multiple Myeloma, Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Leukemia, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Aachen, NW, Germany
Other Locations
Bonn, NW, Germany
Duesseldorf, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Biological, Device, Drug
Study Drugs: IMA203 Product, Atezolizumab
Study Phase: Phase 1/Phase 2
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Device, Drug
Study Drug: IMA202
Study Phase: Phase 1
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors (ACTengine® IMA201-101)
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors (ACTengine® IMA201-101)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Diagnostic test, Biological
Study Drugs: IMA201, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Randomized Controlled Trial Comparing Outcome After Hematopoietic Cell Transplantation From a Partially Matched Unrelated Versus Haploidentical Donor
A Randomized Controlled Trial Comparing Outcome After Hematopoietic Cell Transplantation From a Partially Matched Unrelated Versus Haploidentical Donor
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
View 3 Less Clinical Trials

43 Total Publications

Sepsis and organ failure are the major risks for allogeneic transplant patients in the post- or late- engraftment phase admitted to the ICU.
Sepsis and organ failure are the major risks for allogeneic transplant patients in the post- or late- engraftment phase admitted to the ICU.
Journal: Hematology (Amsterdam, Netherlands)
Published: October 21, 2025

Frequently Asked Questions about Tobias W. Holderried

Is Tobias W. Holderried a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Tobias W. Holderried is classified as an Experienced expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tobias W. Holderried participate in research or clinical trials?

Yes. Tobias W. Holderried has published 43 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Tobias W. Holderried's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Holderried's expertise for a condition
ConditionClose
        View All 12 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile